M
Marco Valgimigli
Researcher at University of Bern
Publications - 772
Citations - 91095
Marco Valgimigli is an academic researcher from University of Bern. The author has contributed to research in topics: Percutaneous coronary intervention & Myocardial infarction. The author has an hindex of 105, co-authored 696 publications receiving 69184 citations. Previous affiliations of Marco Valgimigli include University of Düsseldorf & Erasmus University Medical Center.
Papers
More filters
Journal ArticleDOI
Cyphering the Complexity of Coronary Artery Disease Using the Syntax Score to Predict Clinical Outcome in Patients With Three-Vessel Lumen Obstruction Undergoing Percutaneous Coronary Intervention
Marco Valgimigli,Patrick W. Serruys,Keiichi Tsuchida,Sophia Vaina,Marie Angèle Morel,Marcel van den Brand,Antonio Colombo,Marie Claude Morice,Keith D. Dawkins,Bernard De Bruyne,Ran Kornowski,Stefano De Servi,Giulio Guagliumi,J. Wouter Jukema,Frederick W. Mohr,Arie Pieter Kappetein,Kristel Wittebols,Hans Peter Stoll,Eric Boersma,Giovanni Parrinello +19 more
TL;DR: The SXscore is a promising tool to risk stratify outcome in patients with extensive coronary artery disease undergoing contemporary PCI and compared with the modified lesion classification scheme of the American Heart Association/American College of Cardiology showed a greater discrimination ability and a better goodness of fit with the Hosmer-Lemeshow statistic.
Journal ArticleDOI
Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug eluting stents: meta-analysis of randomised controlled trials
Eliano Pio Navarese,Felicita Andreotti,Volker Schulze,Michalina Kołodziejczak,Antonino Buffon,Marc A. Brouwer,Francesco Costa,Mariusz Kowalewski,Gianfranco Parati,Gregory Y.H. Lip,Malte Kelm,Marco Valgimigli +11 more
TL;DR: Compared with a standard 12 month duration, short term DAPT after drug eluting stent implementation yields reduced bleeding with no apparent increase in ischaemic complications, and could be considered for most patients.
Journal ArticleDOI
International Expert Consensus on Switching Platelet P2Y12 Receptor-Inhibiting Therapies
Dominick J. Angiolillo,Fabiana Rollini,Robert F. Storey,Deepak L. Bhatt,Stefan James,David J. Schneider,Dirk Sibbing,Derek So,Dietmar Trenk,Dimitrios Alexopoulos,Paul A. Gurbel,Willibald Hochholzer,Leonardo De Luca,Laurent Bonello,Daniel Aradi,Thomas Cuisset,Udaya S. Tantry,Tracy Y. Wang,Marco Valgimigli,Ron Waksman,Roxana Mehran,Gilles Montalescot,Francesco Franchi,Matthew J. Price +23 more
TL;DR: This expert consensus provides an overview of the pharmacology of P2y12 inhibitors, different modalities and definitions of switching, and available literature and recommendations for switching between P2Y12 inhibitors.
Journal ArticleDOI
Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention
Daniel Aradi,Ajay J. Kirtane,Laurent Bonello,Paul A. Gurbel,Udaya S. Tantry,Kurt Huber,Matthias K. Freynhofer,Jurriën M. ten Berg,Paul M.L. Janssen,Dominick J. Angiolillo,Jolanta M. Siller-Matula,Rossella Marcucci,Giuseppe Patti,Fabio Mangiacapra,Marco Valgimigli,Olivier Morel,Tullio Palmerini,Matthew J. Price,Thomas Cuisset,Adnan Kastrati,Gregg W. Stone,Dirk Sibbing +21 more
TL;DR: Platelet reactivity assessment during thienopyridine-type P2Y12-inhibitors identifies PCI-treated patients at higher risk for mortality and ST (HPR) or at an elevated risk for bleeding (LPR).
Journal ArticleDOI
Comparison of angioplasty with infusion of tirofiban or abciximab and with implantation of sirolimus-eluting or uncoated stents for acute myocardial infarction: the MULTISTRATEGY randomized trial.
Marco Valgimigli,Gianluca Campo,Gianfranco Percoco,Leonardo Bolognese,Corrado Vassanelli,Salvatore Colangelo,Nicoletta De Cesare,Alfredo E. Rodriguez,Maurizio Ferrario,Raúl Moreno,Tommaso Piva,Imad Sheiban,Giampaolo Pasquetto,Francesco Prati,Marco Stefano Nazzaro,Giovanni Parrinello,Roberto Ferrari +16 more
TL;DR: Tirofiban therapy was associated with noninferior resolution of ST-segment elevation at 90 minutes following coronary intervention, whereas sirolimus-eluting stent implantation wasassociated with a significantly lower risk of major adverse cardiac events than uncoated stents within 8 months after intervention.